| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
TD Cowen analyst Charles Rhyee maintains Medpace Hldgs (NASDAQ:MEDP) with a Sell and raises the price target from $356 to $462.
Barclays analyst Luke Sergott maintains Medpace Hldgs (NASDAQ:MEDP) with a Underweight and raises the price target from $425...
Mizuho analyst Ann Hynes maintains Medpace Hldgs (NASDAQ:MEDP) with a Outperform and raises the price target from $575 to $655.
Medpace shares climb as Q3 earnings and revenue top estimates, driven by strong bookings, rising backlog, and an upbeat 2025 gu...